Device Trial Radar · NCT07235007
Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 20, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Aichi Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This international, multicenter, open-label randomized controlled trial evaluates whether repeated endobiliary radiofrequency ablation (EB-RFA) improves overall survival in patients with unresectable extrahepatic cholangiocarcinoma undergoing first-line systemic therapy with durvalumab plus gemcitabine and cisplatin (GCD). Eligible patients will be randomized 1:1 to EB-RFA with plastic stent placement or standard plastic stenting alone. A scheduled second endoscopic session will be performed at 3 months in both groups (repeat EB-RFA only in the EB-RFA arm). The primary endpoint is overall survival. Secondary endpoints include time to recurrent biliary obstruction, progression-free survival, adverse events, and technical/clinical success.
Conditions
- Extrahepatic Cholangiocarcinoma
Interventions
Endobiliary Radiofrequency Ablation (EB-RFA)Device
Endobiliary RFA performed using the ELRA® catheter (STARmed) with VIVA combo® generator. Recommended settings: 7-10 W, temperature control 80 °C, 120 seconds per application. Applied along the full stricture length. Repeat procedure at Month 3 (window 2-4 months). Additional sessions every ≥2 months permitted if imaging suggests ablatable residual lesion.
Plastic Biliary StentDevice
Placement of 7Fr or 8.5Fr plastic biliary stent from hepatic side of the stenosis to the duodenum. Bilateral preferred for hilar strictures; unilateral acceptable based on drainage.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From randomization until death from any cause (up to 36 months after last enrollment)
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Aichi Medical University
Aichi, Japan · Recruiting
Nagoya City University Hospital
Aichi, Japan · Recruiting
Nagoya City University Midori Municipal Hospital
Aichi, Japan · Recruiting
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.